According to the report from Zhitong Finance APP, the CDE website shows that astrazeneca (AZN.US)'s antisense therapy Eplontersen (IONIS-TTR-LRx, trade name: Wainua) has applied to be listed in China for the treatment of hereditary transthyretin-mediated amyloidosis polyneuropathy (ATTRv-PN). ATTRv-PN can lead to peripheral nerve damage and motor disorders within five years of diagnosis. If left untreated, patients typically die within ten years. It is estimated that there are approximately 0.3-0.5 million cases of ATTR-CM globally, with around 0.04 million cases of ATTRv-PN.

Public information shows that Eplontersen (IONIS-TTR-LRx) is a ligand-conjugated antisense oligonucleotide (LICA) drug designed to reduce the production of serum TTR for the treatment of hereditary and non-hereditary ATTR. The drug was approved for market in the USA in December 2023. Under the global development and commercialization agreement between astrazeneca and Ionis, the two companies will jointly develop and commercialize Eplontersen in the USA, while astrazeneca will be responsible for the development and commercialization in the rest of the world (excluding Latin America).